FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 24, 2026
BioCardia, Inc. (BCDA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $8.2 million. Free cash flow was -$7.4 million. As of Jun 30, 2026 it held $4.1 million in cash and investments and $293,000 in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-8.23M
-3.5% vs prior year
Operating cash flow (TTM)
$-7.56M
+9.0% vs year-ago TTM
Free cash flow (TTM)
$-7.57M
+8.9% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
10.94M
+133.8% vs prior year
Net cash
$3.82M
as of Jun 30, 2026
Operating margin
-13794.8%
FY 2024
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sunnyvale, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 925741
- Former names
- Tiger X Medical, Inc. (until Oct 17, 2016); Cardo Medical, Inc. (until May 25, 2011); CLICKNSETTLE COM INC (until Oct 20, 2008); NAM CORP (until Mar 29, 2000)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $58,000 | $477,000 | $1.4M | $1.0M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M | -$12.6M |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M | -$12.6M |
| Operating cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.4M |
| Free cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.5M |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M | $15.7M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M | $5.3M |
| Stockholders' equity | $895,000 | $837,000 | -$1.6M | $4.9M | $10.4M |
| Cash and investments | $2.5M | $2.4M | $1.1M | $7.4M | $12.9M |
| Total debt | $528,000 | $951,000 | $1.3M | $1.6M | $1.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
All 1002 BioCardia, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.